Search
Zhixiang Jintai and Cullinan Ink Licensing and Commercialization Pact for GR1803 Injection
2025-06-05 /
Read about 0 minute
Author：小编
Zhixiang Jintai has entered into an agreement with Cullinan to collaboratively develop and commercialize GR1803 Injection, a therapeutic agent designed to treat moderate to severe active rheumatoid arthritis. Under the terms of the agreement, Zhixiang Jintai has secured exclusive licensing rights within Greater China, committing to upfront fees, milestone payments, and royalties tied to net sales. Conversely, Cullinan retains the rights to development, production, and commercialization in territories beyond Greater China.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
